Camurus (Buy, TP: SEK296.00) - Updating assumptions post CRL
Instead of an official approval for Brixadi in the US market, Camurus’s partner Braeburn received a Complete Response Letter. The CRL was related to issues at Braeburn’s CMO, and we do not yet know the details of the FDA findings. However, we believe a 6-month delay in the US approval is likely and therefore we have changed our forecast. Camurus’s loss in the arbitration process with Braeburn does not change our forecasts as this was our base case. We reiterate our BUY but have trimmed our target price to SEK296 (SEK309) on the delayed US approval and a stronger SEK.Camurus AB is a Sweden-based research and development based pharmaceutical company with a focus on the development and commercialization of specialty medicines, providing patients suffering from serious and chronic disease, such as opioid dependence, pain, cancer, acromegaly, and neuroendocrine tumors. The Company has a diversified research portfolio, which includes five products in clinical trials, and a number of additional product candidates in the pre-clinical phase. The Company's product pipeline represents a mix of in-house and partnered projects in different development phases. Camurus AB is the parent company of the Group, which comprises four legal entities, namely Camurus Inc, Cubosome Inc, Camurus Development AB and Bioimplant Scandinavia AB.
DNB Markets is the investment banking arm of DNB Bank ASA and is focused primarily on the Nordic region, as well as internationally on niches such as global shipping, energy and related services, and seafood. DNB Markets offers services in FICC, Equities and Investment Banking advisory from offices in Oslo, Stockholm, London, Singapore and New York. Equity research coverage is offered on c250 Nordic companies. DNB was ranked no.2 in Extel Nordic Research 2017. The DNB Markets’ Credit and FICC Macro & FX Research teams are repeatedly highly rated by Prospera Nordic Institutional Investor Surveys.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.